Q-omics provides the consensus-scored CACNA2D3 profile across patient tissues and cancer cell-line models. CACNA2D3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CACNA2D3 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, CACNA2D3 RNA expression shows 20,559 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, KIRC, and GBM as cancer lineages where CACNA2D3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CACNA2D3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CACNA2D3 survival associations across molecular data types. CACNA2D3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CACNA2D3 RNA expression–survival associations across cancer types. High CACNA2D3 expression shows unfavorable associations in UCEC, STAD and LAML, but favorable associations in HNSC, LGG and CHOL. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CACNA2D3 RNA expression.
This table summarizes CACNA2D3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CACNA2D3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CACNA2D3 shows lower tumor expression in KIRC, KICH, KIRP, STAD and COAD and higher tumor expression in LIHC. The KIRC box plot shows higher CACNA2D3 RNA expression in normal versus tumor tissue (log2 FC = −1.627, t-test p < 0.001).
This table shows molecular features associated with CACNA2D3 in patient tissues and cancer cell lines. In patient samples, CACNA2D3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CACNA2D3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
